The autocrine effect of activin a on human ovarian clear cell adenocarcinoma cells

Oncology Reports

Volumn 16, Issue 2, 2006, Pages 373-379

  Mabuchi, Yasushi ^a   Yamoto, Mareo ^b   Minami, Sawako ^a   Umesaki, Naohiko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b WAKAYAMA ROSAI HOSPITAL   (Japan)

Author keywords

Activin; Activin receptor; Cell growth; Clear cell adenocarcinoma; Inhibin; Ovarian cancer; Phosphorylated Smad; Smad

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR; INHIBIN; SMAD PROTEIN; SMAD2 PROTEIN;

ADENOCARCINOMA; ARTICLE; AUTOCRINE EFFECT; CELL CULTURE; CELL PROLIFERATION; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PHOSPHORYLATION;

ACTIVIN RECEPTORS; ACTIVINS; ADENOCARCINOMA, CLEAR CELL; AUTOCRINE COMMUNICATION; CELL PROLIFERATION; FEMALE; HUMANS; INHIBIN-BETA SUBUNITS; OVARIAN NEOPLASMS; PHOSPHORYLATION; SMAD PROTEINS; SMAD2 PROTEIN; TUMOR CELLS, CULTURED;

EID: 33748579926     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.2.373     Document Type: Article

References (40)

1. Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000. (Pubitemid 30331967)
2. Tammela J, Geisler JP, Eskew PN and Geisler HE: Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 19: 438-440, 1998. (Pubitemid 28479390)
3. Itamochi H, Kigawa J, Akeshima R, et al: Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 62: 349-353, 2002. (Pubitemid 34914104)
4. Massague J: Transforming growth factor beta family. Annu Rev Cell Biol 6: 597-641, 1990.
5. Mason AJ, Hayflick JS, Ling N, et al: Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-β. Nature 318: 659-663, 1985. (Pubitemid 16172414)
6. Lapolt PS and Hsueh AJW: Moleculer basis of inhibin production and action. Mol Cell Neurosci 2: 449-463, 1991.
7. Vale W, Rivier C, Hsueh AJW, et al: Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44: 1-34, 1988.
8. Nakao A, Imamura T, Souchelnytskyi S, et al: TGF-β receptor-mediated signaling through Smad2, Smad3, and Smad4. EMBO J 16: 5353-5362, 1997. (Pubitemid 27380143)
9. Whitman M: Smads and early developmental signaling by the TGF-β superfamily. Genes Dev 12: 2445-2462, 1998.
10. Yue J and Mulder KM: Requirement of RAS/MAPK pathway activation by transforming growth factor-β1 production in a Smad-dependent pathway. J Biol Chem 275: 30765-30773, 2000.
11. Yue J and Mulder KM: Transforming growth factor-β signal transduction in epithelial cells. Pharmacol Ther 91: 1-34, 2001. (Pubitemid 33055772)
12. Woodruff TK and Mather JP: Inhibin, activin and the female reproductive axis. Annu Rev Physiol 57: 219-244, 1995.
13. Risbridger GP, Schmitt JF and Robertson DM: Activin and inhibins in endocrine and other tumors. Endocr Rev 22: 836-858, 2001. (Pubitemid 34214298)
14. Attisano L and Tuen Lee-Hoeflich S: The Smads. Genome Biol 2: 3010.1-3010.8, 2001.
15. Shi Y, Hata A, Lo RS, Massague J and Pavletich NP: A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388: 87-93, 1997. (Pubitemid 27283894)
16. Massague J: TGF-β signal transduction. Annu Rev Biochem 67: 753-791, 1998.
17. Pangas SA and Woodruff TK: Activin signal transduction pathways. Trends Endocrinol Metab 11: 309-314, 2000.
18. Lewis KA, Gray PC, Blount AL, et al: Betaglycan binds inhibin and can mediate functional antagonism of activin signaling. Nature 404: 411-414, 2000. (Pubitemid 30164345)
19. Yamashita K, Yamoto M, Shikone T, et al: Production of inhibin A and inhibin B in human ovarian sex cord stromal tumors. Am J Obstet Gynecol 177: 1450-1457, 1997. (Pubitemid 28040242)
20. Yamashita K, Yamoto M, Shikone T, Minami S and Nakano R: Immunohistochemical localization of inhibin and activin subunits in human epithelial ovarian tumors. Am J Obstet Gynecol 180: 316-322, 1999. (Pubitemid 29093859)
21. Mabuchi Y, Yamoto M, Minami S and Umesaki N: Immunohistochemical localization of inhibin and activin subunits, activin receptors, and Smads in ovarian clear cell adenocarcinoma. Oncol Rep 15: 291-296, 2006.
22. Yamada K, Tachibana T, Hashimoto H, et al: Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5, JHOC-6) of human ovary. Hum Cell 12: 131-138, 1999.
23. Muttukrishna S, Fowler PA, Geoge L, Groome NP and Knight PG: Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab 81: 3328-3334, 1996. (Pubitemid 26296211)
24. Groome NP, Illingworth PJ, O'Brien M, et al: Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol 40: 717-723, 1994. (Pubitemid 24216620)
25. Menon U, Riley SC, Thomas J, et al: Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. Br J Obstet Gynaecol 107: 1069-1074, 2000.
26. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF and Schneyer AL: Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 82: 3720-3727, 1997. (Pubitemid 27509361)
27. McPherson SJ, Mellor SL, Wang H, Evans LW, Groome NP and Risbridger GP: Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 140: 5303-5309, 1999.
28. Lambert-Messerlian GM, Depasquale SE, Maybruck WM, Steinhoff MM and Gajewski WH: Secretion of activin A in recurrent epithelial ovarian carcinoma. Gynecol Oncol 74: 93-97, 1999. (Pubitemid 29331173)
29. Ito I, Minegishi T, Fukuda J, Shinozaki H, Auersperg N and Leung PCK: Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma. Br J Cancer 82: 1415-1420, 2000. (Pubitemid 30175907)
30. Fuller PJ, Zumpe ET, Chu S, Mamers P and Burger HG: Inhibin-activin receptor subunit gene expression in ovarian tumors. J Clin Endocrinol Metab 87: 1395-1401, 2002. (Pubitemid 36121114)
31. Dunfield LD, Dwyer EJC and Nachtigal MW: TGF-β induced Smad signaling remains intact in primary human ovarian cancer cells. Endocrinology 143: 1174-1181, 2002. (Pubitemid 34274344)
32. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ and Bradley A: Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360: 313-319, 1992. (Pubitemid 23000668)
33. Shikone T, Matzuk M, Perlas E, et al: Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p-53 deficient mice: the role of activin as an autocrine growth factor. Mol Endocrinol 8: 983-985, 1994.
34. Di Simone N, Crowley WF, Wang QF, Sluss PM and Schneyer AL: Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137: 486-494, 1996. (Pubitemid 26049884)
35. Choi KC, Kang SK, Nathwani PS, Cheng KW, Auersperg N and Leung PCK: Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE). Mol Cell Endocrinol 174: 99-110, 2001. (Pubitemid 32288873)
36. Steller MD, Shaw TJ, Vanderhyden BC and Ethier JF: Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res 3: 50-61, 2005. (Pubitemid 40189596)
37. Zauberman A, Oren M and Zipori D: Involvement of p21WAF1/Cip1, CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition. Oncogene 15: 1705-1711, 1997. (Pubitemid 27466710)
38. Ho J, De Guise C, Kim C, Lemay S, Wang XF and Lebrun JJ: Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1. Cell Signal 16: 693-701, 2004. (Pubitemid 38490551)
39. Danila DC, Inder WJ, Zhang X, et al: Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Metab 85: 1009-1015, 2000. (Pubitemid 32269341)
40. Burdette JE, Jeruss JS, Kurkley SJ, Lee EJ and Woodruff TK: Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 65: 7968-7975, 2005. (Pubitemid 41297276)